Seminars in Hematology
Volume 47, Issue 2 , Pages 143-147 , April 2010

Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab

  • Michael Bennett

      Affiliations

    • Department of Hematology, Ha'Emek Medical Center, Afula, Israel
    • ,
  • Geraldine P. Schechter

      Affiliations

    • Hematology Section, Veterans Affairs Medical Center, and George Washington University, Washington, DC
    • Corresponding Author InformationAddress correspondence to Geraldine P. Schechter, MD, Hematology Section, Veterans Affairs Medical Center, George Washington University, Washington, DC 20422

References 

  1. Melo JV, Robinson DS, Gregory C, Catovsky D. Splenic B cell lymphoma with “villous” lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia. Leukemia. 1987;1:294–298
  2. Schmid C, Kirkham N, Diss T, Isaacson PG. Splenic marginal zone cell lymphoma. Am J Surg Pathol. 1992;16:455–466
  3. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lympho-cytes/splenic marginal-zone lymphoma. Semin Hematol. 1999;36:148–154
  4. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994;83:1558–1562
  5. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22:487–495
  6. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008;
  7. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120:759–764
  8. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients (Groupe Francais d'Hematologie Cellulaire (GFHC)). Br J Haematol. 1996;93:731–736
  9. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78:206–209
  10. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41–47
  11. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006;107:125–135
  12. Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica. 2005;90:856–858
  13. Bennett M, Yegena S, Dave HP, Schechter GP. Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2008;26:114
  14. Kalpadakis C, Pangalis GA, Dimopoulou MN, et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol. 2007;25:127–131
  15. Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma. 2004;4:250–252
  16. Cervetti G, Galimberti S, Sordi E, et al. Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. October 13, 2009;Epub ahead of print
  17. Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648–1654
  18. Iannitto E, Ambrosetti A, Ammatuna E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes (Hematologic findings and outcomes in a series of 57 patients). Cancer. 2004;101:2050–2057
  19. Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol. 1997;99:158–161
  20. Lefrere F, Levy V, Francois S, et al. Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia. 2004;18:1924–1925
  21. Lefrere F, Hermine O, Francois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma. 2000;40:113–117
  22. Riccioni R, Caracciolo F, Galimberti S, Cecconi N, Petrini M. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol. 2003;21:163–168
  23. Iannitto E, Minardi V, Calvaruso G, et al. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol. 2005;75:130–135
  24. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;2:4079–4088
  25. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–2745
  26. Lossos IS, Morgensztern D, Blaya M, Alencar A, Pereira D, Rosenblatt J. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. Leuk Lymphoma. 2007;48:1630–1632
  27. Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009;145:741–748
  28. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91:294–301
  29. Thomsen RW, Schoonen WM, Farkas DK, et al. Risk for hospital contact with infection in patients with splenectomy (A population-based cohort study). Ann Intern Med. 2009;151:546–555
  30. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114:2861–2868
  31. Jais X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax. 2005;60:1031–1034

PII: S0037-1963(10)00005-3

doi: 10.1053/j.seminhematol.2010.01.004

Seminars in Hematology
Volume 47, Issue 2 , Pages 143-147 , April 2010

Article Tools